Drug discovery platform for peptides with dual therapeutic modality

SignaBlok, Inc. is a biopharmaceutical company founded in 2009 that focuses on developing novel mechanism-based targeted therapeutics and nanosystems for delivery and diagnostic imaging [1]. The company utilizes its proprietary Signaling Chain HOmoOLigomerization (SCHOOL) platform, which enables ligand-independent drug development for immune receptor signaling modulation [2][4]. This approach aims to address significant limitations found in traditional ligand-dependent models, offering potential applications across a wide range of inflammation-associated conditions, including cancer, autoimmune diseases, retinopathy, and sepsis [3][4].

By targeting specific pathways such as TREM-1 and TREM-2, SignaBlok seeks to provide innovative interventions for diseases characterized by unmet clinical needs [3][4]. The company maintains an extensive intellectual property portfolio that supports its drug discovery and diagnostic development efforts [7]. Through strategic partnerships and collaborations, SignaBlok works to translate its scientific research into practical medical solutions for patients [8]. The organization is led by Dr. Alexander B. Sigalov, whose experience in fields including immunology and biophysics guides the company’s ongoing pipeline development [1].